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Abstract
Background: Many patients with tuberculosis (TB) are seropositive for human herpesvirus type 8 (HHV-8), and
many patients with primary effusion lymphoma have high levels of HHV-8 DNA in their effusions. However, the
status of HHV-8 in the effusions of patients with TB remains unclear.
Methods: Blood samples were collected from 129 patients with pulmonary TB and 129 age- and sex-matched
healthy controls. Forty of the TB patients had pleural or peritoneal effusions, and 38 of these effusions were
available. Both blood and effusion samples were analyzed for lymphocyte and monocyte counts and/or HHV-8
antibodies and DNA.
Results: TB patients with or without effusions had significantly greater HHV-8 seropositivity (p = 0.009) and titers of
HHV-8 antibodies (p = 0.005) than healthy controls. The seropositivity and blood titers of HHV-8 antibodies were
similar in TB patients with and without effusions. Among TB patients with effusions, similar percentages had
seropositive plasma and seropositive effusions. Plasma samples of 6 TB patients, but none of the healthy controls,
were positive for HHV-8 DNA (p = 0.03). TB patients with or without effusions had lower blood lymphocyte counts
and higher blood monocyte counts than healthy controls (p < 0.0001 for both). TB patients with effusions had
significantly lower blood lymphocyte counts than those without effusions (p = 0.035).
Conclusions: HHV-8 had similar seroprevalence in TB patients with and without effusions. However, TB patients
with effusions had lower blood lymphocyte counts than those without effusions.
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Background
Previous studies have consistently identified human her-
pesvirus type 8 (HHV-8) DNA in patients with all types
of Kaposi’s sarcoma (KS), and this virus is considered
the etiological agent for KS [1, 2]. Healthy individuals
with HHV-8 infections typically have no symptoms or
signs of disease. However, HHV-8-infected patients with
diverse immunologic abnormalities [3, 4], such as those
with the human immunodeficiency virus (HIV) infec-
tion, can develop KS.
HIV-infected patients have a decreased number
of circulating CD4+ T-lymphocytes. Depletion of T-
lymphocytes in general and CD4+ cells in particular also
occurs in patients with tuberculosis (TB) [5, 6].
Moreover, patients with HIV infection or pulmonary TB
have peripheral blood mononuclear cells with impaired
interferon-γ production upon in vitro antigenic stimula-
tion, as well as aberrant in vivo T-cell activation [7].
There is also a high HHV-8 seroprevalence in HIV-
infected or pulmonary TB patients without KS [8–11].
Primary effusion lymphoma (PEL) occurs mostly in
HIV-infected patients, and is associated with HHV-8 in-
fection [12]. The HHV-8 DNA levels in effusion samples
from patients with PEL are significantly higher than
those in blood samples [13]. However, the presence of
HHV-8 antibodies and DNA in the plasma and effusions
of TB patients with pleural or peritoneal effusion has
not yet been determined.
Patients with active TB are more likely to have lympho-
penia and monocytosis [7, 14, 15]. Thus, we evaluated the
associations of HHV-8 infection with lymphopenia and
monocytosis in TB patients with and without effusions. In
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particular, we assessed the positivity and titers of HHV-8
antibodies and the positivity and levels of HHV-8 DNA in
blood and effusion samples of TB patients with pleural or
peritoneal effusions.
Methods
Subjects and sample collection
All patients had newly diagnosed pulmonary TB and
were examined before treatment. TB was initially sus-
pected based on clinical features and abnormalities on
chest radiographs, and confirmed by identifying Mycobac-
terium tuberculosis from sputum cultures in Löwenstein–
Jensen medium. Patients with abdominal fullness, fever,
and even dyspnea were suspected of having peritoneal ef-
fusion. These patients were given chest and/or abdominal
CT exams, with aspiration of the peritoneal effusion using
an echo-guide. The collected pleural and peritoneal effu-
sions were studied for routine biochemistry including
polymerase chain reaction (PCR) and mycobacterial
culture for TB detection, and measurement of adenosine
deaminase (ADA). Definite TB effusion was indicated by
positive culture or PCR results. Patients without culture
or PCR positivity were reassessed 2 months after the initi-
ation of anti-TB treatment if they had a predominance of
lymphocytes, high level of serum protein, and ADA
greater than 40 mg/mL. Because of the high prevalence
and the need for legal notification, the final TB diagnosis
was discussed and determined by an official committee of
Centers for Disease Control of Taiwan based on clinical
information and treatment outcome. Patients with add-
itional heart, lung, or other major diseases were excluded.
The study protocol was approved by the Institutional
Review Board of the Buddhist Dalin Tzu Chi Hospital
(B09602001 and B09703021). All individuals provided
informed written consent for participation.
Plasma samples were collected following medical ex-
aminations of 129 patients with pulmonary TB and 129
age- and sex-matched healthy controls. Forty of the TB
patients had pleural or peritoneal effusions, and 38 of
these effusions were available. All samples were collected
in sterile tubes and centrifuged immediately at 4 °C to
remove cells. Aliquots of the supernatants were frozen
at −70 °C until analysis of HHV-8 antibodies and DNA.
The lymphocyte and monocyte counts of peripheral
blood from healthy controls and TB patients were ana-
lyzed using an automated hematologic analyzer (XE-2100,
Sysmex, Kobe, Japan) before plasma sample collection.
The mean ages of the 91 male controls (62.5 ±
12.6 years) and the 38 female controls (58.9 ± 17.2 years)
were similar (p = 0.18; t test), as were the mean ages of
the 91 male TB patients (62.3 ± 12.6 years) and the 38
female TB patients (58.9 ± 17.2 years) (p = 0.22; t-test).
The mean ages of TB patients with effusions (60.1 ±
17.1 years; 29 men and 11 women) and without effusion
(61.8 ± 12.6 years; 62 men and 27 women) were also
similar (p = 0.52; t-test). All patients and controls were
negative for HIV antibodies.
Immunofluorescence assay (IFA) for HHV-8 antibodies
A commercially available IFA kit (Advanced Biotech-
nologies Inc, Columbia, MD) was used to detect HHV-8
immunoglobulin G (IgG) antibodies against the lytic
antigens in plasma and effusion samples according to
the manufacturer’s instructions. This assay was based on
HHV-8-infected body cavity lymphoma cell lines. Plasma
or effusion samples at various dilutions were brought
into contact with fixed infected cells and examined
microscopically using a fluorescence microscope. Sam-
ples that displayed fluorescence at a dilution of 1:40
were considered positive. Maximum HHV-8 antibody
dilutions were determined by end-point IFA.
DNA extraction and amplification of HHV-8 DNA
HHV-8 DNA was extracted and PCR-amplified from each
patient’s plasma and effusion as reported previously [11].
Chemiluminescence immunoassay for HIV antibody
Plasma samples were assayed for antibodies to HIV-1
and HIV-2 using the Vitros anti-HIV 1 + 2 reagent pack,
control, and calibrator (Ortho-Clinical Diagnostics, High
Wycombe, England) and the Vitros ECi immunodiag-
nostic system (Ortho-Clinical Diagnostics, Rochester,
NY) according to the manufacturer’s instructions.
Statistical analysis
A χ2 test or Fisher’s exact test was used to assess the
significance of between-group differences in categorical
variables. The significance of differences in the means of
continuous variables from two groups was determined
using the t-test. The comparison of plasma anti-HHV-8
titers in healthy controls and TB patients was analyzed
using the Mann–Whitney test. A p-value less than
0.05 was considered significant. Statistical analyses
were performed using SPSS version 12.0 for Windows
(SPSS, Chicago, IL).
Results
Twenty-two healthy controls (17.1 %, 17 males and 5
females) and 40 TB patients (31.0 %, 29 men and 11
women) were positive for HHV-8 antibodies. The HHV-8
seropositivity rate and titers of HHV-8 antibodies were
significantly greater in TB patients than in healthy con-
trols (p = 0.009 by χ2 test and p = 0.005 by Mann–Whitney
test, respectively) (Table 1). The mean ages were similar in
healthy subjects who were seropositive and seronegative,
in TB patients who were seropositive and seronegative,
and in TB patients with or without effusions (p > 0.05 for
all 3 comparisons; t-test). The seropositivity rate was also
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similar in male and female healthy controls, in male and
female TB patients, and in TB patients with and without
effusions (p > 0.05 for all 3 comparisons by χ2 or Fisher’s
exact test).
Patients with effusions (n = 40) and without effusions
(n = 89) had similar HHV-8 seropositivity, titer of
HHV-8 antibodies, and HHV-8 DNA positivity in plasma
(p = 0.56 by χ2 test; p = 0.45 by Mann–Whitney test; and
p = 0.67 by Fisher’s exact test, respectively) (Table 2).
The effusion samples of 2 TB patients with pleural
effusions were unavailable, but the plasma of 1 of these
patients was positive for HHV-8 DNA (472 copies/mL)
(Table 2). The positive rates and titers of HHV-8 anti-
bodies in the plasma and effusion samples of the
remaining 38 patients with effusions (3 with ascites and
35 with pleural effusion) were similar (p = 0.45 by χ2 test;
p = 0.50 by Mann–Whitney test, respectively) (Table 3).
The plasma and effusion samples of the 38 patients
whose effusions were available were all negative for
HHV-8 DNA.
The plasma samples of 3 of the 89 patients without
effusions who were negative for HHV-8 antibodies
were positive for HHV-8 DNA (544, 899, and 1011
copies/mL). Moreover, 2 of the patients without effu-
sions who were positive for HHV-8 antibodies were
positive for HHV-8 DNA (1415 and 3720 copies/mL).
Thus, the plasma samples of 6 TB patients, but none
of the healthy controls, were positive for HHV-8
DNA (p = 0.03) (Table 1).
TB patients had much lower blood lymphocyte and
monocyte counts than healthy controls (p < 0.0001 for
both; t-test) (Table 1). However, controls who were
seronegative and seropositive, and patients who were
seronegative and seropositive had similar blood lympho-
cyte counts (1838 ± 501/μL vs. 1783 ± 471/μL and 1322 ±
656/μL vs. 1222 ± 673/μL, respectively; p > 0.05 for both;
t-test) and similar blood monocyte counts (318 ± 109/
μL vs. 301 ± 115/μL and 546 ± 251/μL vs. 565 ± 368/
μL, respectively; p > 0.05 for both; t-test).
TB patients with effusions had significantly lower
blood lymphocyte counts than those without effusions
(1112 ± 452/μL vs. 1380 ± 729/μL; p = 0.035; t-test)
(Table 2). Among TB patients with and without effu-
sions, blood lymphocyte counts were similar for those
who were HHV-8 seronegative and seropositive (1125 ±
448/μL vs. 1078 ± 484/μL and 1428 ± 727/μL vs. 1283 ±
793/μL, respectively; p > 0.05 for both; t-test). Blood
monocyte counts in HHV-8 seronegative and seroposi-
tive TB patients with and without effusion were also
similar (534 ± 222/μL vs. 621 ± 428/μL and 552 ± 268/μL
vs. 542 ± 346/μL, respectively; p > 0.05 for both; t-test).
None of the TB patients who were positive for HHV-8
antibodies or HHV-8 DNA had clinical manifestations of
HHV-8 infection, such as KS, PEL, or Castleman
disease.
Discussion
The major finding of the present study is that HIV-
negative individuals with pulmonary TB, both with and
without effusions, had greater seropositivity for anti-
HHV8 antibodies than age- and sex-matched healthy
controls. These results are in line with the results of our
previous study of subjects with TB pneumonia [11]. The
cutoff point for HHV-8 seropositivity in the present
Table 1 Age, lymphocyte count, monocyte count, HHV-8 seropositivity, titer of anti-HHV-8 antibodies, and presence of HHV-8 DNA







IFA (+) rateb Anti-HHV-8 with maximal dilution HHV-8
DNA1:40 1:80 1:160 1:320 1:640 1:1280
Healthy controls 61.4 ± 14.1 1829 ± 495 315 ± 110 17.1 % (22/129) 15 6 0 0 1 0 0
P value <0.0001c <0.0001c 0.009d 0.005e 0.03f
TB patients 61.3 ± 14.1 1291 ± 661g 552 ± 291g 29.7 % (40/129) 21 11 2 2 3 1 6
HHV-8 human herpesvirus type 8, IFA mmunofluorescence assay, TB tuberculosis
aMean ± standard deviation. bPositive in the IFA. ct-test. dχ2 test. eMann–Whitney test. fFisher’s exact test. gLymphocyte and monocyte counts of 9 TB patients
were unavailable
Table 2 Age, lymphocyte count, monocyte count, HHV-8 seropostitivity, titer of anti-HHV-8 antibodies, and presence of HHV-8 DNA







IFA (+) rateb Anti-HHV-8 HHV-8
DNA1:40 1:80 1:160 1:320 1:640 1:1280
TB patients with effusion 40 60.1 ± 17.1 1112 ± 452 558 ± 290 27.5 % (11/40) 7 3 0 1 0 0 1
P value 0.52 0.035c 0.87c 0.56d 0.45e 0.67f
TB patients without effusion 89 61.8 ± 12.6 1380 ± 729g 549 ± 293g 32.6 % (29/89) 14 8 2 1 3 1 5
HHV-8 human herpesvirus type 8, IFA mmunofluorescence assay, TB tuberculosis
aMean ± standard deviation. bPositive in the IFA. ct-test. dχ2 test. eMann–Whitney test. fFisher’s exact test. gLymphocyte and monocyte counts of 9 TB patients
without effusions were unavailable
Tsao et al. BMC Infectious Diseases  (2015) 15:489 Page 3 of 6
study was set at 1:40 according to the manufacturer’s in-
structions. In our recent study of HHV-8 seroprevalence
in patients with end-stage renal disease, one of the two
healthy controls with IFA antibody titers of 1:160
displayed positivity in a specific enzyme-linked im-
munosorbent assay (ELISA) [16]. If the cutoff point
for seropositivity was set at 1:160 in our previous
study, then the seropositive rate among TB patients
was marginally higher (5/101 vs. 0/101; p = 0.059;
Fisher’s exact test) [11], but in the present study the
seropositive rate would remain significantly higher in
patients than in controls (8/129 vs. 1/129; p = 0.036;
Fisher’s exact test). This discrepancy might be due to
fewer subjects in the previous study.
The present study demonstrated that the seropreva-
lence of HHV-8 was similar among TB patients with and
without effusions (27.5 vs. 32.6 %). As noted in our pre-
vious study of subjects with pulmonary TB [11], HHV-8
seroprevalence in HIV-negative TB patients with pleural
effusions was lower than in HIV-negative patients with
KS (52–100 %) and comparable to that in HIV-positive
patients without KS (13–50 %) [8–10, 17]. This suggests
that HHV-8 infection has similar roles in TB patients
with and without effusions. However, the study groups
enrolled in the present and previous studies were much
older than individuals who have the greatest risk for
HIV infection.
Previous studies reported that the prevalence of HHV-8
infection increases with age [18–20], and that KS is more
common in elderly males [21]. Our previous comparison
of TB patients and healthy controls [11] indicated similar
prevalence of HHV-8 seropositivity for males and females
and similar mean ages for seropositive and seronegative
subjects. In agreement, the present study demonstrated
similar seropositivity for males and females, similar mean
ages for seronegative and seropositive subjects, and similar
seropositivity for TB patients with and without effusions.
Our previous study reported similar positivity for
HHV-8 DNA in TB patients and healthy controls (4/101
vs. 0/101, p = 0.12) [11]. However, the present study
indicated that HHV-8 DNA positivity was significantly
greater in the TB group than in the control group (6/129
vs. 0/129, p = 0.03). These discrepant findings might be
attributable to smaller number of subjects in our pre-
vious study.
Our previous study of patients with cirrhosis and ascites
indicated the positive rate and titers of anti-HHV-8
antibodies were much greater in plasma than ascites
(p < 0.0001) [22]. Among cirrhosis patients, the posi-
tive rate of anti-HHV-8 antibodies in plasma samples
was more than 6-fold greater than in effusion sam-
ples. By contrast, the present study indicated similar
positive rates and titers of anti-HHV-8 antibodies in
plasma and effusion samples among TB patients with
effusions (13/38 vs. 10/38, p = 0.45). The most likely
reason for this difference is that TB effusions are exu-
dates, but cirrhosis effusions are transudates [23].
HHV-8 is associated with PEL, a rare form of malig-
nant clonal B-cell lymphoproliferation [12]. Among
patients with PEL, the level of HHV-8 DNA in effusion
samples is significantly higher than in blood samples
[13]. In contrast, the present study found that plasma
and effusion samples from the 38 TB patients with avail-
able effusions were all negative for HHV-8 DNA. This
suggests that the role of HHV-8 is different for patients
with TB and those with PEL.
The present study found that TB patients with or
without effusions had lower lymphocyte counts and
higher monocyte counts than healthy controls (p <
0.0001 for both), in agreement with our previous study
of patients with TB pneumonia [11]. Stimulated pleural
macrophages can induce production of interleukin-8
(IL-8) protein, and IL-8 in turn can induce lymphocyte
chemotaxis into the pleural space [24]. Hence, lympho-
cyte counts are elevated in the effusions of patients with
TB [25]. This may explain the finding of the present
study that TB patients with peritoneal or pleural effu-
sions had significantly lower blood lymphocyte counts
than those without effusions (p = 0.035).
These are four limitations in the present study. First,
although this is the first study to comprehensively investi-
gate the prevalence of HHV-8 in TB patients with periton-
eal or pleural effusions, all participants were recruited
from a single teaching hospital. Thus, the results may not
be representative of the overall situation in Taiwan or else-
where in the world. Second, the PCR method used in this
study can only detect 5–10 copies of HHV-8 DNA, and
therefore may be insufficiently sensitive for definitively
establishing the presence or absence of HHV-8 DNA. The
question of whether patients such as those who partici-
pated in this study have HHV-8 DNA at levels less than
5–10 copies/mL be resolved if the detection sensitivity
can be increased. Third, we did not investigate the poten-
tial for a common underlying cause of both TB and HHV-
8 infection, such as socioeconomic status, nutritional con-
ditions, and health-related behaviors. Fourth, we did not
Table 3 Number of TB patients who tested positive for anti-HHV-8
antibodies in plasma and in peritoneal or pleural effusion samples
Plasma Effusion P value




HHV-8, human herpesvirus type 8; IFA, immunofluorescence assay;
TB, tuberculosis
aPositive in the IFA. bEffusion specimens of 2 of the 40 TB patients with
effusions were unavailable. cχ2 test. dMann-Whitney test
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have records of any co-morbidities or adjunct therapies in
our TB population, and we expect these to be relatively
common in older individuals, such as those in our study
population.
Conclusion
The seropositivity and titers of anti-HHV-8 antibodies
and the seropositivity of HHV-8 DNA were significantly
higher in TB patients with or without peritoneal or
pleural effusions than in healthy controls. The preva-
lence of HHV-8 in TB patients with or without effusions
is comparable to that previously reported for HIV-
infected patients without KS. Thus, our study suggests
that TB patients with or without effusions are vulnerable
to HHV-8 infection, similar to HIV-infected patients.
We also found that the seropositivity and titers of anti-
HHV-8 antibodies and the seropositivity of HHV-8
DNA were similar for TB patients with and without
effusions, suggesting a similar role for HHV-8 in these
two groups of TB patients. TB patients with effusions
had significantly lower blood lymphocyte counts than
those without effusions. This may be attributable to IL-8
production mediated by stimulated peritoneal or pleural
macrophages and the subsequent induction of lympho-
cyte chemotaxis into the body cavities.
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